| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CX31 |
| Uniprot No | O75712 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-270aa |
| 氨基酸序列 | MDWKTLQALLSGVNKYSTAFGRIWLSVVFVFRVLVYVVAAERVWGDEQKDFDCNTKQPGCTNVCYDNYFPISNIRLWALQLIFVTCPSLLVILHVAYREERERRHRQKHGDQCAKLYDNAGKKHGGLWWTYLFSLIFKLIIEFLFLYLLHTLWHGFNMPRLVQCANVAPCPNIVDCYIARPTEKKIFTYFMVGASAVCIVLTICELCYLICHRVLRGLHKDKPRGGCSPSSSASRASTCRCHHKLVEAGEVDPDPGNNKLQASAPNLTPI |
| 预测分子量 | 30,8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CX31重组蛋白的模拟参考文献示例(非真实文献，仅供格式参考)：
1. **文献名称**: "Expression and Purification of Recombinant Connexin31 in Escherichia coli"
**作者**: Smith A, et al.
**摘要**: 本研究报道了在大肠杆菌系统中高效表达并纯化CX31重组蛋白的方法，通过优化诱导条件和亲和层析技术获得可溶性蛋白，为后续体外通道功能研究奠定基础。
2. **文献名称**: "Functional Analysis of CX31 Mutants Associated with Erythrokeratodermia"
**作者**: Lee J, et al.
**摘要**: 文章利用哺乳动物细胞表达系统研究CX31疾病相关突变体(如G12D)的通道形成能力，发现突变导致细胞间通讯障碍，揭示其与皮肤病理的分子机制。
3. **文献名称**: "Crystallographic Study of Human Connexin31 Hemichannel Structure"
**作者**: Wang Y, et al.
**摘要**: 通过X射线晶体学解析了重组CX31蛋白的六聚体结构，揭示了跨膜区关键氨基酸对通道门控的调控作用，为靶向药物设计提供结构基础。
4. **文献名称**: "Interactions Between CX31 and ZO-1 Protein in Epithelial Cells"
**作者**: Tanaka K, et al.
**摘要**: 利用重组CX31蛋白及免疫共沉淀技术，证实其与紧密连接蛋白ZO-1的相互作用，探讨了CX31在细胞极性维持中的潜在功能。
注：以上内容为模拟生成，实际文献需通过学术数据库(如PubMed、Web of Science)检索确认。
**Background of CX31 Recombinant Protein**
CX31. or Connexin 31. is a member of the connexin family of transmembrane proteins that form gap junctions, critical channels enabling direct intercellular communication. These channels facilitate the exchange of ions, metabolites, and signaling molecules (≤1 kDa), coordinating cellular activities in tissues. Encoded by the *GJB3* gene in humans, CX31 is primarily expressed in the epidermis, inner ear, and peripheral nerves, playing roles in skin homeostasis, auditory function, and neural signaling.
Mutations in *GJB3* are linked to hereditary disorders, including erythrokeratodermia variabilis (EKV), a skin condition characterized by hyperkeratosis and erythema, and nonsyndromic hearing loss. Such mutations disrupt gap junction assembly or function, impairing cell-cell communication and leading to disease phenotypes. To study these mechanisms, recombinant CX31 proteins are generated via heterologous expression systems (e.g., *E. coli*, mammalian cells). These purified proteins retain functional domains, enabling in vitro studies on channel properties, mutant behavior, and interactions with therapeutic candidates.
Recombinant CX31 is pivotal for structural analyses (e.g., cryo-EM) to map channel architecture and mutation-induced conformational changes. It also aids in drug screening for conditions caused by connexin dysfunction. Additionally, it serves as an antigen for antibody development in diagnostic tools. Despite challenges in expressing full-length membrane proteins, advances in solubilization and refolding techniques have enhanced CX31 recombinant production, supporting both basic research and translational applications in dermatology, neurology, and otology.
In summary, CX31 recombinant protein is a vital tool for unraveling the pathophysiology of connexin-related diseases and advancing targeted therapies.
×
